The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients
Abstract
OBJECTIVE: For patients with locally advanced and unresectable pancreatic cancer (PDAC), neodadjuvant treatment and consecutive surgical exploration have been studied during the last decade with various neoadjuvant therapies including chemotherapy and combinations with radiation. Aim of the study was the evaluation of neoadjuvant therapy with a focus on Folfirinox. METHODS: All consecutive patients undergoing surgery for PDAC after neoadjuvant treatment were analyzed (clinico-pathological characteristics, secondary resection rates, outcome). Patients receiving Folfirinox were compared with other treatment regimens. RESULTS: Between December 2001 and June 2015, 575 patients received neoadjuvant treatment and were scheduled for resection after re-staging. A successful resection was achieved in 292 patients (50.8%). Resection rates following Folfirinox were 61% (76/125 patients) compared with 46% (150/322 patients) after gemcitabine and radiation, and 52% (66/128 patients) after other treatments (P = 0.026). Median overall survival was 15.3 months after resection vs 8.5 months after exploration alone (P < 0.0001). Subgroup median survival was 16.0 months (Folfirinox) vs 16.5 months (gemcitabine) and 14.5 months (others) with 3-year survival of 28.1%, 23.2%, and 19.7%, respectively (P = 0.8582). By multivariable analysis, Folfirinox was confirmed to be independently associated with a favorable prognosis. CONCLUSIONS: Folfirinox is a valuable treatment option in the neoadjuvant therapy of PDAC. From the present data, which represent the largest available study population to date, Folfirinox seems to be the most effective protocol resulting in a significantly better secondary resection rate and overall survival than other treatments. It should be considered in all patients fit for this regimen and consecutive surgical exploration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Bockhorn, M., Uzunoglu, F. G., Adham, M., Imrie, C., Milicevic, M., Sandberg, A. A., Asbun, H. J., Bassi, C., Büchler, M., Charnley, R. M., et al. (2014) · Surgery · doi:10.1016/j.surg.2014.02.001 · Cited by 967
Self-citationFerrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 842
Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome
Hartwig, W., Hackert, T., Hinz, U., Gluth, A., Bergmann, F., Strobel, O., Büchler, M. W., & Werner, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31821fd334 · Cited by 412
Self-citationHartwig, W., Strobel, O., Hinz, U., Fritz, S., Hackert, T., Roth, C., Büchler, M. W., & Werner, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2809-1 · Cited by 301
Self-citationBlazer, M., Wu, C., Goldberg, R. M., Phillips, G., Schmidt, C., Muscarella, P., Wuthrick, E., Williams, T. M., Reardon, J., Christopher Ellison, E., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4225-1 · Cited by 244
Mellon, E. A., Hoffe, S. E., Springett, G. M., Frakes, J. M., Strom, T. J., Hodul, P. J., Malafa, M. P., Chuong, M. D., & Shridhar, R. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1004367 · Cited by 241
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Christians, K. K., Tsai, S., Mahmoud, A., Ritch, P., Thomas, J. P., Wiebe, L., Kelly, T., Erickson, B., Wang, H., Evans, D. B., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0273 · Cited by 190
Meta-analysis of radical resection rates and margin assessment in pancreatic cancer
Chandrasegaram, M. D., Goldstein, D., Simes, J., Gebski, V, Kench, J. G., Gill, A. J., Samra, J. S., Merrett, N. D., Richardson, A. J., & Barbour, A. P. (2015) · British Journal of Surgery · doi:10.1002/bjs.9892 · Cited by 188
Cited by
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Self-citationSurvival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection
Gemenetzis, G., Groot, V. P., Blair, A. B., Laheru, D. A., Zheng, L., Narang, A. K., Fishman, E. K., Hruban, R. H., Yu, J., Burkhart, R. A., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002753 · Cited by 401
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Self-citationPancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 348
Metadata
- Authors
- Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A., & Büchler, M. W.
- Venue
- Annals of Surgery
- Published
- 2016-09
- Volume
- 264
- Issue
- 3
- Pages
- 457-463
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2465801062
- Cited by
- 529
- References
- 18
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. https://app.cochat.ai/papers/10.1097/sla.0000000000001850
- The paper
- Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A., & Büchler, M. W. (2016). Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Annals of Surgery. https://doi.org/10.1097/sla.0000000000001850
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.